Skip to content

Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert

Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert - a Multicenter Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01720394
Enrollment
253
Registered
2012-11-02
Start date
2013-11-30
Completion date
2019-12-31
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Ripening, Induction of Labor

Brief summary

The purpose of the study is to determine the efficacy of a silicone-double-balloon-catheter for cervical ripening and labor induction in women with unfavorable cervix (Bishop Score not greater than 6) compared to medical treatment using a dinoprostone slow-release-vaginal-insert.

Interventions

DEVICECervical Ripening Balloon, Cook Medical Inc.

Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.

DRUGDinoprostone

Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.

Sponsors

Medical University of Vienna
CollaboratorOTHER
Medical University Innsbruck
CollaboratorOTHER
Klinikum Klagenfurt am Wörthersee
CollaboratorOTHER
University of Salzburg
CollaboratorOTHER
Hospital Hartberg, Austria
CollaboratorUNKNOWN
Hospital Braunau, Austria
CollaboratorUNKNOWN
Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* medical indication for induction of labor * 18 years of age * signed informed consent * cephalic presentation * no PROM * 37+0 - 42+0 weeks of gestation * Bishop-Score ≤ 6 * no contra-indication for medical induction of labor * no clinical signs of infection

Exclusion criteria

* fetal anomalies * contra-indications for medical induction of labor * placental pathologies * St.p. surgery with opening the uterine cavity (incl. caesarean section) * PROM * multiple gestations * \< 37-0 weeks of gestation * St.p. cervical tear

Design outcomes

Primary

MeasureTime frameDescription
time interval from primary treatment to deliverymaximum of 72 hoursthe time interval between the first application of the cervical ripening balloon (therapy arm 1) to delivery and the time between first application of dinoprostone vaginal-insert (therapy arm 2) to delivery is measured

Secondary

MeasureTime frameDescription
vaginal deliverymaximum of 72 hoursNumber of patients who achieve spontaneous vaginal delivery or vaginal-operative delivery in therapy arm 1 and 2.
failed induction of labormaximum of 72 hoursNumber of patients who received caesarean section after frustrating induction of labor. Frustrating induction is defined as application of the cervical-ripening-balloon + 2 times application of dinoprostone-vaginal-insert in therapy arm 1 and 3 times application of dinoprostone-vaginal-insert in therapy arm 2.
progress of labormaximum of 72 hourstime from balloon-application to dilatation of the cervix (cervical opening \> 3cm, or Bishop Score ≥ 9 ) in therapy arm 1 and from dinoprostone-vaginal-insert-application to dilatation of the cervix (cervical opening \> 3cm, or Bishop Score ≥ 9 ) in therapy arm 2
maternal parametersprimary treatment - 48h postpartal, leading to a maximum time frame of 5 dayssigns of infection (temperature, CRP, WBC), childbirth--related injuries,need for epidural in therapy arm 1 and 2.
fetal parametersprimary treatment - fetal hospital discharge, with an expected maximum of 3 monthsumbilical cord blood values, apgar score, fetal birth weight,number of admissions to ICU and days at ICU in therapy arm 1 and 2.
patient's satisfactionparticipants will be followed for the duration of hospital stay, an expected average of 5-7 daysPatient's satisfaction with treatment is evaluated with a questionnaire within 48 h after delivery

Countries

Austria

Contacts

Primary ContactPhilipp Reif, MD
philipp.reif@medunigraz.at004331638580053
Backup ContactPhilipp Klaritsch, MD
philipp.klaritsch@medunigraz.at004331638581641

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026